Value investing message boards image Log on |  Join ($$) Stock market forums image VF "How To" Guide        Welcome, guest! Learn about guest access               Home
• Related Discussion Forum Messages
As a ValueForum member, this section would contain CORT message board posts where the ticker symbol CORT has been mentioned by ValueForum members in posts. Learn more about guest access, and benefits of membership -- we hope you will consider joining ValueForum or trying out our service with a 24 hour trial pass.

• Latest CORT SEC Filings

Filings Format Description Filing Date File/Film Number
4  Documents Statement of changes in beneficial ownership of securities
Acc-no: 0000899243-17-028552 Size: 9 KB
4  Documents Statement of changes in beneficial ownership of securities
Acc-no: 0000899243-17-028495 Size: 8 KB
4  Documents Statement of changes in beneficial ownership of securities
Acc-no: 0000899243-17-026822 Size: 4 KB
4  Documents Statement of changes in beneficial ownership of securities
Acc-no: 0001225208-17-017372 Size: 10 KB
10-Q  Documents   Interactive Data Quarterly report [Sections 13 or 15(d)]
Acc-no: 0001564590-17-021314 (34 Act)  Size: 4 MB
2017-11-03 000-50679
8-K  Documents Current report, items 2.02, 7.01, and 9.01
Acc-no: 0001171843-17-006573 (34 Act)  Size: 95 KB
2017-11-02 000-50679
UPLOAD  Documents [Cover]SEC-generated letter
Acc-no: 0000000000-17-034015 Size: 136 KB
CORRESP  Documents [Cover]Correspondence
Acc-no: 0001193125-17-291069 Size: 15 KB
UPLOAD  Documents [Cover]SEC-generated letter
Acc-no: 0000000000-17-032275 Size: 144 KB
8-K  Documents Current report, item 7.01
Acc-no: 0001193125-17-272504 (34 Act)  Size: 17 KB
2017-08-30 000-50679
More CORT SEC Filings

Related news from
Wed, 13 Dec 2017
22:45:10 +0000
Regeneron, Sanofi Report Positive Top Line Skin Cancer Data
Regeneron (REGN) and partner Sanofi announced positive top-line results from a pivotal phase II study of skin cancer candidate cemiplimab.
Wed, 13 Dec 2017
20:46:08 +0000
Allergan Inks Deal to Buy Texas-Based Repros Therapeutics
Allergan (AGN) signs a definitive contract to acquire Texas-based Repros Therapeutics, which is focused on developing new drugs to treat hormonal and reproductive system disorders.
Wed, 13 Dec 2017
18:01:43 +0000
ETFs with exposure to Corcept Therapeutics, Inc. : December 13, 2017
Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to Corcept Therapeutics, Inc. Here are 5 ETFs with the largest exposure to CORT-US. Comparing the performance and risk of Corcept Therapeutics, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker ... Read more <b>(Read more...)</b>
Wed, 13 Dec 2017
14:40:02 +0000
Glaxo's Nucala Label Expansion Application Gets FDA Approval
GlaxoSmithKline's (GSK) application to include treatment of eosinophilic granulomatosis with polyangiitis in Nucala's label was approved by the FDA.
Tue, 12 Dec 2017
22:58:10 +0000
Merck's Keytruda Gets FDA Priority Review for Rare Lymphoma
Merck (MRK) informs that the FDA grants a priority review to its supplemental biologics license application looking for its marketed drug Keytruda's label expansion for a rare lymphoma indication.
Tue, 12 Dec 2017
15:15:03 +0000
Spark Therapeutics Stock Plunges on Hemophilia Therapy Data
Spark Therapeutics (ONCE) plunged 35% as investors were not impressed by the data from a phase I/II study on its Hemophilia A candidate, SPK-8011.
Mon, 11 Dec 2017
19:12:07 +0000
Lilly Reports Mixed Results from Late-Stage Cyramza Study
Lilly's (LLY) gastric cancer drug, Cyramza, meets primary endpoint of progression free survival in a phase III study in first-line advanced gastric cancer patients. However, it failed to improve overall survival.
Thu, 07 Dec 2017
21:28:28 +0000
5 Health Care Stocks Gurus Are Buying
Gurus are investing in these popular stocks
Thu, 07 Dec 2017
19:21:07 +0000
Roche Reports Tecentriq/Avastin Lung Cancer Study Data
Roche (RHHBY) announced interim results from the phase III IMpower150 study of Tecentriq and Avastin plus chemotherapy in people with advanced form of lung cancer.
Wed, 06 Dec 2017
19:10:07 +0000
Revance's Neuromodulator Injection Positive in Phase III
Revance (RVNC) releases positive top-line data from two pivotal phase III trials, evaluating RT002 for reducing wrinkles between the brows. The studies meet both primary and secondary endpoints.
Tue, 05 Dec 2017
14:46:02 +0000
Here's Why Sarepta Stock is Up More Than 70% in 6 Months
Sarepta's (SRPT) key product, Exondys 51, and lead pipeline candidate, golodirsen, have put up a good show in the past six months.
Tue, 05 Dec 2017
14:05:02 +0000
Ironwood Succeeds in Diabetic Hypertension Phase II Study
Ironwood Pharmaceuticals' (IRWD) pipeline candidate, IW-1973, reduces blood pressure and improves metabolic parameters in type II diabetes with hypertension patients in a phase IIa study.
Mon, 04 Dec 2017
13:07:00 +0000
3 Highest Growth Stocks in the Market Today
Profit growth doesn't get any faster than this.
Fri, 01 Dec 2017
23:14:11 +0000
Bristol-Myers' Opdivo's Lung Cancer Study Meets Early Success
Bristol-Myers' (BMY) phase III study evaluating Opdivo versus docetaxel was stopped earlier than expected as it met the primary endpoint.
Fri, 01 Dec 2017
22:51:10 +0000
Celldex Begins Phase I Trial on Cancer Candidate CDX-1140
Celldex (CLDX) commences a phase I study on CDX-1140 for patients with advanced solid tumors. The study is designed to evaluate the safety and tolerability of the candidate at different dose levels.
Wed, 29 Nov 2017
14:52:02 +0000
AstraZeneca's Tagrisso Label Expansion Filing Accepted by EMA
AstraZeneca's (AZN) Marketing Authorisation Application for label expansion of Tagrisso has been accepted by the European Medicines Agency.
Wed, 22 Nov 2017
13:42:01 +0000
Valeant Closes Senior Note Offering, Reprices Term Loan
Valeant (VRX) offered new debt and restructured old debt. The company is making efforts to repay its huge level of debt.
Tue, 21 Nov 2017
17:37:22 +0000
Edited Transcript of CORT earnings conference call or presentation 2-Nov-17 9:00pm GMT
Q3 2017 Corcept Therapeutics Inc Earnings Call
Tue, 21 Nov 2017
14:15:02 +0000
Can Valeant (VRX) Turn Around on Rebuilding Initiatives?
Valeant (VRX) has performed much better so far in 2017 compared to last year on the back of rebuilding initiatives.
Mon, 20 Nov 2017
21:07:09 +0000
Mallinckrodt (MNK) Down 55% Year to Date: What Lies Ahead?
Mallinckrodt plc (MNK)'s stock lost 55% in the year so far due to ongoing investigations and weakness in Acthar and Inomax.

"ValueForum is an active, private, online discussion community for stock & bond market investing. In discussion forums divided into finely grained topics, you will find sophisticated investors trading tips, research, and due diligence on value stocks, income investments, forex, market news, and more. Join in - trade ideas, strategies, current news, via our unique message bulletin boards, stock ratings system, and other online tools specifically geared toward our community."

Random member testimonial: "I absolutely LOVE ValueForum, and consider this site the most important tool I have for investing and/or trading because of the incredible information at just one site. I have learned so much from reading messages posted here that I recommend to the new comer to select an area of investing that is of interest and then read those posts starting with most current. I am sure you will gain information and learn techniques that can be applied to other areas/sectors of investing. This is an 'Invaluable' forum." more testimonials »

Email / About | Privacy | Terms of Use | How To / FAQ | Msg Ticker | VF Home | My.vf | BDCs.vf | Energy.vf | REITs.vf | TA.vf
Nothing in is intended to be investment advice, nor does it represent the opinion of, counsel
from, or recommendations by ©2003 - 2017, Powered in part by Ticker TechnologiesContact Us

Stock Market Investing Forum - Trading Tips & Research - Online Message Boards